Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nanna L Lausvig

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|June 9, 2024
Familywise error for multiple time-to-event endpoints in a group sequential designHenrik F Thomsen, Nanna L Lausvig, Christian B Pipper, et al.
Diabetologia|January 4, 2020
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trialRory J McCrimmon, Andrei-Mircea Catarig, Juan P Frias, et al.
The Lancet. Diabetes & Endocrinology|September 22, 2019
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trialIldiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, et al.
Diabetes, Obesity & Metabolism|October 15, 2019
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trialsVanita R Aroda, Matthew S Capehorn, Louis Chaykin, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|June 9, 2024
Familywise error for multiple time-to-event endpoints in a group sequential designHenrik F Thomsen, Nanna L Lausvig, Christian B Pipper, et al.
Diabetologia|January 4, 2020
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trialRory J McCrimmon, Andrei-Mircea Catarig, Juan P Frias, et al.
The Lancet. Diabetes & Endocrinology|September 22, 2019
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trialIldiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, et al.
Diabetes, Obesity & Metabolism|October 15, 2019
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trialsVanita R Aroda, Matthew S Capehorn, Louis Chaykin, et al.
Pageof 1